Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients - Top-Institutions - MDSpire

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

  • By

  • H. Habibullah

  • M. Alotaibi

  • H. Almarzouki

  • Z. Mulla

  • M. Elbaiomy

  • R. Alahmadi

  • A. Ahmed

  • Y. Bahadur

  • R. Ujaimi

  • E. Senan

  • M. Attar

  • A. Bamakhramah

  • H. Altoukhi

  • H. Muamenah

  • O. Iskanderani

  • R. Garout

  • J. Alturkistani

  • H. Hijazi

  • Z. Jastaniah

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Institute of Cancer Research
    The Institute of Cancer Research

    London, England

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    King Faisal Specialist Hospital & Research Centre
    King Faisal Specialist Hospital & Research Centre

    Riyadh, Saudi Arabia

    Key Differentiators

    • Oncology

  • #4

    King Abdulaziz University Hospital
    King Abdulaziz University Hospital

    Jeddah, Saudi Arabia

    Key Differentiators

    • Oncology

  • #5

    University of Utah
    University of Utah

    Salt Lake City, Utah

    Key Differentiators

    • Oncology

Original Source(s)

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

  • by H. Habibullah, M. Alotaibi, H. Almarzouki, Z. Mulla, M. Elbaiomy, R. Alahmadi, A. Ahmed, Y. Bahadur, R. Ujaimi, E. Senan, M. Attar, A. Bamakhramah, H. Altoukhi, H. Muamenah, O. Iskanderani, R. Garout, J. Alturkistani, H. Hijazi, Z. Jastaniah

  • June 10, 2026

Related Content

Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition

Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening

Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study